Trial Profile
An Analysis of Efficacy of Maintenance Dasatinib for Ph+ALL Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Phase II trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2019
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms DASALL II
- 11 Mar 2019 Status changed from not yet recruiting to recruiting.
- 19 Feb 2018 New trial record